Pillar
Sleep
This category covers peptides studied for sleep — improving sleep depth, architecture, and onset. The most-discussed are DSIP (delta sleep-inducing peptide) and the growth-hormone secretagogues, which deepen slow-wave sleep as a byproduct of stimulating GH release. The evidence is mostly small-study and mixed.
Reviewed by Marko Maal, MSc Pharmacy · University of Tartu · Pharmaceutical sciences — drug sourcing, formulation, regulatory review · Reviewed Jun 7, 2026
Reviewed for clinical and pharmacological accuracy by Marko Maal, MSc Pharmacy.
Sleep is one of the goals peptides are most often reached for — and one where the evidence is thinnest and most mixed. This pillar covers the peptides studied for sleep depth, architecture, and onset, with honest framing about what the data does and doesn't support.
What peptides are used for sleep?
Two groups dominate the conversation. DSIP (delta sleep-inducing peptide) is the one named for sleep itself, though its human evidence is old and limited. The growth-hormone secretagogues — CJC-1295 with ipamorelin, sermorelin — are widely reported to deepen slow-wave sleep, because growth hormone is released during deep sleep and these peptides stimulate that axis. That overlap is exactly why sleep and growth hormone were historically discussed together.
How strong is the evidence?
Modest. The clearest signal is that GH secretagogues can increase slow-wave (deep) sleep in small studies, a plausible knock-on of stimulating the GH axis. DSIP's evidence is sparse and dated. As with most of this space, the rational expectation is a possible improvement in sleep quality for some people, not a reliable sleep aid — and standard sleep hygiene, light exposure, and addressing underlying causes remain the foundation.
For the deeper dives, see the linked articles below.
Supporting articles
Does DSIP actually work for sleep, and how does it compare to GH-axis peptides?
Yes — modestly. DSIP is a 9-aa peptide isolated in the 1970s that produces modest, well-tolerated sleep-architecture improvement in published trials. Effect size is smaller than GH-axis peptides. Mechanism remains partially characterized. Niche but legitimate for isolated sleep goals, GH-axis contraindications, or stress-mediated insomnia.
Do GH-axis peptides actually improve sleep, and how do sleep-primary protocols differ from body-comp protocols?
Yes — modestly. Slow-wave sleep triggers the dominant overnight GH pulse; sermorelin or CJC-1295 (no DAC) + ipamorelin at bedtime amplify that pulse and produce measurable SWS-time increase and subjective sleep-quality improvement. Effect emerges over 2-4 weeks. Not first-line for sleep apnea, insomnia, or circadian misalignment.
Community Notes
0 approved · moderated
Structured notes from readers — context, citations, corrections, and first-hand experience. Every note is moderated before it appears. Notes do not replace medical review; they supplement it.
No approved notes yet.
Know something that should be on this page? A citation, clarification, or dispute? Sign in and submit the first note.
Submission interface coming in Phase 2. For now, notes are authored in Studio. See the Community Guidelines for moderation criteria.